The breakthrough and the future: CD20 chimeric antigen receptor T-cell therapy for hematologic malignancies

Abstract

Chimeric antigen receptors (CAR) T-cell therapy is one of the most effective treatments in curing hematologic malignancies. Besides the four CD19 CAR T-cells therapy recently approved by the US Food and Drug Administration (FDA), CD20 CAR T-cell therapy is now another effective treatment option for relapsed or refractory non-Hodgkin lymphoma (NHL). CD20 CAR T-cell infusion has achieved remarkable clinical outcomes in patients with B-cell malignancies. This review will cover the current situations, advantages, limitations, prospects, and application of CD20 CAR T-cell therapy.